<DOC>
	<DOC>NCT01112397</DOC>
	<brief_summary>This study is being conducted to assess the safety, tolerability and PK of AZD1480 in patients with advanced solid malignancies.</brief_summary>
	<brief_title>Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Patients with advanced solid cancer without available therapy in the escalation phase and mutation positive NSCLC or nonsmokers with other primary tumors lung metastasis in the expansion phase ECOG Performance Status 01 Evidence of postmenopausal status in females or males willing to use barrier contraception Prior therapy with any JAK2 medications Significant lung disorder or lung disease. Previous radiation therapy to chest wall or chest infection requiring antibiotic treatment within 21 days before study screening. Evidence of significant pulmonary hypertension or COPD Eye disease of the cornea</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Jak2</keyword>
	<keyword>cancer</keyword>
	<keyword>jak 1</keyword>
	<keyword>stat 3</keyword>
	<keyword>Phase 1</keyword>
</DOC>